KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash & Current Investments (2016 - 2026)

Bio-Rad Laboratories has reported Cash & Current Investments over the past 18 years, most recently at $1.6 billion for Q1 2026.

  • Quarterly Cash & Current Investments fell 5.76% to $1.6 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.6 billion through Mar 2026, down 5.76% year-over-year, with the annual reading at $1.5 billion for FY2025, 7.44% down from the prior year.
  • Cash & Current Investments was $1.6 billion for Q1 2026 at Bio-Rad Laboratories, up from $1.5 billion in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $2.1 billion in Q1 2022 and troughed at $409.4 million in Q4 2023.
  • The 5-year median for Cash & Current Investments is $1.4 billion (2025), against an average of $1.1 billion.
  • Year-over-year, Cash & Current Investments plummeted 77.35% in 2023 and then soared 306.57% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $439.8 million in 2022, then dropped by 6.91% to $409.4 million in 2023, then soared by 306.57% to $1.7 billion in 2024, then fell by 7.44% to $1.5 billion in 2025, then grew by 1.56% to $1.6 billion in 2026.
  • Per Business Quant, the three most recent readings for BIO's Cash & Current Investments are $1.6 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.4 billion (Q3 2025).